The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era

This Perspective describes the challenges of prescribing exercise for weight loss, with and without the use of glucagon-like peptide 1 (GLP-1) receptor agonists, and discusses strategies clinicians can use to improve adherence to exercise recommendations.

Corresponding Author: Daniel E. Lieberman, PhD, Department of Human Evolutionary Biology, Harvard University, 11 Divinity Ave, Cambridge, MA 02138 (danlieb@fas.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.